PLX logo

Protalix BioTherapeutics (PLX) Selling, General & Administrative Expenses

Annual SGA

$14.96 M
+$3.25 M+27.73%

December 31, 2023

Summary

Performance

1-Year Change

+27.73%

3-Year Change

+34.19%

5-Year Change

+37.04%

15-Year Change

+29.74%

PLX SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

34.52%
PLX annual SGA is higher than 34.52% of companies in Healthcare sector

High & Low

All-time High

$20.59 M
PLX annual SGA is currently -27.36% below its historical high of $20.59 million

3-Year Low

$11.71 M
PLX annual SGA is currently +27.73% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
PLX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 14, 2025
PLX next annual earnings announcement is scheduled for Mar 14, 2025

OtherPLXexpensesmetrics:

Annual Total Expenses

$55.03 M
PLX annual total expenses is $55.03 million

Annual Operating Expenses

$32.05 M
PLX annual total operating expenses is $32.05 million

Annual Cost Of Goods Sold

$22.98 M
PLX annual cost of goods sold is $22.98 million

Annual Interest Expense

$3.18 M
PLX annual interest expense is $3.18 million

Quarterly SGA

$2.60 M
-$889.00 K-25.52%

September 30, 2024

Summary

Performance

3-Month Change

-25.52%

1-Year Change

-29.29%

3-Year Change

-29.29%

5-Year Change

-29.29%

PLX Quarterly SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

22.03%
PLX quarterly SGA is higher than 22.03% of companies in Healthcare sector

High & Low

All-time High

$10.12 M
PLX quarterly SGA is currently -74.35% below its historical high of $10.12 million

3-Year Low

$2.60 M
PLX quarterly SGA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
PLX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
PLX next earnings announcement is scheduled for Mar 14, 2025

OtherPLXexpensesmetrics:

Quarterly Total Expenses

$13.97 M
PLX quarterly total expenses is $13.97 million

Quarterly Operating Expenses

$5.59 M
PLX quarterly total operating expenses is $5.59 million

Quarterly Cost Of Goods Sold

$8.38 M
PLX quarterly cost of goods sold is $8.38 million

Quarterly Interest Expense

$299.00 K
PLX quarterly interest expense is $299.00 thousand

TTM SGA

-$1.54 B
-$9.38 M-0.61%

September 30, 2024

Summary

Performance

3-Month Change

-10788.86%

1-Year Change

-11171.43%

3-Year Change

-11171.43%

5-Year Change

-11171.43%

PLX TTM SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

32.18%
PLX TTM SGA is higher than 32.18% of companies in Healthcare sector

High & Low

All-time High

-$2.23 M

3-Year Low

-$1.55 B

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
PLX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
PLX next earnings announcement is scheduled for Mar 14, 2025

OtherPLXexpensesmetrics:

Annual Total Expenses

$55.03 M
PLX annual total expenses is $55.03 million

Annual Operating Expenses

$32.05 M
PLX annual total operating expenses is $32.05 million

TTM Cost Of Goods Sold

$29.29 M
PLX TTM cost of goods sold is $29.29 million

TTM Interest Expense

$1.83 M
PLX TTM interest expense is $1.83 million

Selling, General & Administrative Expenses Formula

SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development

Annual SGA

$14.96 M
PLX annual SGA is $14.96 million

Annual Operating Expenses

$32.05 M
PLX annual total operating expenses is $32.05 million

Annual Cost Of Goods Sold

$22.98 M
PLX annual cost of goods sold is $22.98 million

PLX Selling, General & Administrative Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+27.7%-29.3%-10000.0%
3 y3 years+34.2%-29.3%-10000.0%
5 y5 years+37.0%-29.3%-10000.0%

PLX Selling, General & Administrative Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+27.7%-37.4%at low-310.9%+0.7%
5 y5-yearat high+51.1%-37.4%+18.3%-310.9%+0.7%
alltimeall time-27.4%>+9999.0%-74.3%>+9999.0%<-9999.0%+0.7%

Protalix BioTherapeutics Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sep 2024
-
$2.60 M(-25.5%)
$13.34 M(-7.5%)
Jun 2024
-
$3.48 M(+11.8%)
$14.41 M(-3.7%)
Mar 2024
-
$3.12 M(-24.8%)
$14.96 M(0.0%)
Dec 2023
$14.96 M(+27.7%)
$4.14 M(+12.9%)
$14.96 M(+7.5%)
Sep 2023
-
$3.67 M(-9.0%)
$13.91 M(+6.3%)
Jun 2023
-
$4.03 M(+29.4%)
$13.09 M(+12.2%)
Mar 2023
-
$3.12 M(+0.5%)
$11.67 M(-0.3%)
Dec 2022
$11.71 M(-8.0%)
$3.10 M(+8.8%)
$11.71 M(-3.0%)
Sep 2022
-
$2.85 M(+9.1%)
$12.08 M(-0.9%)
Jun 2022
-
$2.61 M(-17.2%)
$12.19 M(-4.4%)
Mar 2022
-
$3.15 M(-9.0%)
$12.74 M(+0.1%)
Dec 2021
$12.73 M(+14.2%)
$3.47 M(+17.3%)
$12.73 M(+4.2%)
Sep 2021
-
$2.95 M(-6.8%)
$12.21 M(+1.1%)
Jun 2021
-
$3.17 M(+1.1%)
$12.08 M(+8.8%)
Mar 2021
-
$3.14 M(+6.3%)
$11.10 M(-0.4%)
Dec 2020
$11.15 M(+12.6%)
$2.95 M(+4.8%)
$11.15 M(-0.6%)
Sep 2020
-
$2.82 M(+28.4%)
$11.21 M(+2.1%)
Jun 2020
-
$2.19 M(-31.2%)
$10.98 M(+1.2%)
Mar 2020
-
$3.19 M(+5.7%)
$10.86 M(+9.7%)
Dec 2019
$9.90 M(-9.3%)
$3.01 M(+16.5%)
$9.90 M(+9.3%)
Sep 2019
-
$2.59 M(+25.1%)
$9.06 M(-14.2%)
Jun 2019
-
$2.07 M(-7.3%)
$10.56 M(-0.8%)
Mar 2019
-
$2.23 M(+2.7%)
$10.65 M(-2.5%)
Dec 2018
$10.92 M(-5.3%)
$2.17 M(-46.9%)
$10.92 M(-9.7%)
Sep 2018
-
$4.09 M(+89.4%)
$12.09 M(+11.6%)
Jun 2018
-
$2.16 M(-13.6%)
$10.84 M(-5.7%)
Mar 2018
-
$2.50 M(-25.3%)
$11.49 M(-0.3%)
Dec 2017
$11.53 M(+23.2%)
$3.34 M(+17.9%)
$11.53 M(+1.8%)
Sep 2017
-
$2.84 M(+0.8%)
$11.33 M(+7.8%)
Jun 2017
-
$2.81 M(+10.9%)
$10.51 M(+6.1%)
Mar 2017
-
$2.54 M(-19.2%)
$9.90 M(+5.8%)
Dec 2016
$9.36 M(+28.5%)
$3.14 M(+56.0%)
$9.36 M(+24.6%)
Sep 2016
-
$2.01 M(-8.7%)
$7.51 M(-1.9%)
Jun 2016
-
$2.21 M(+10.6%)
$7.66 M(+2.8%)
Mar 2016
-
$2.00 M(+54.3%)
$7.45 M(+2.4%)
Dec 2015
$7.28 M(-21.1%)
$1.29 M(-40.2%)
$7.28 M(-8.2%)
Sep 2015
-
$2.16 M(+8.1%)
$7.92 M(+1.9%)
Jun 2015
-
$2.00 M(+9.8%)
$7.77 M(+5.9%)
Mar 2015
-
$1.82 M(-6.0%)
$7.34 M(-20.5%)
Dec 2014
$9.23 M(+14.6%)
$1.94 M(-3.6%)
$9.23 M(-0.5%)
Sep 2014
-
$2.01 M(+28.5%)
$9.28 M(+2.6%)
Jun 2014
-
$1.57 M(-57.8%)
$9.04 M(-6.4%)
Mar 2014
-
$3.71 M(+86.9%)
$9.66 M(+20.0%)
Dec 2013
$8.05 M(-17.5%)
$1.99 M(+11.6%)
$8.05 M(-5.0%)
Sep 2013
-
$1.78 M(-18.4%)
$8.47 M(-4.9%)
Jun 2013
-
$2.18 M(+3.8%)
$8.91 M(-12.9%)
Mar 2013
-
$2.10 M(-12.7%)
$10.24 M(+4.9%)
Dec 2012
$9.76 M(+40.9%)
$2.41 M(+8.6%)
$9.76 M(+8.8%)
Sep 2012
-
$2.22 M(-36.6%)
$8.97 M(+8.4%)
Jun 2012
-
$3.50 M(+115.1%)
$8.28 M(+25.9%)
Mar 2012
-
$1.63 M(+0.7%)
$6.57 M(-5.2%)
Dec 2011
$6.93 M
$1.62 M(+6.0%)
$6.93 M(-12.1%)
Sep 2011
-
$1.53 M(-15.2%)
$7.88 M(+1.3%)
DateAnnualQuarterlyTTM
Jun 2011
-
$1.80 M(-9.6%)
$7.78 M(+7.4%)
Mar 2011
-
$1.99 M(-22.6%)
$7.25 M(+5.4%)
Dec 2010
$6.88 M(-3.8%)
$2.57 M(+80.9%)
$6.88 M(-9.6%)
Sep 2010
-
$1.42 M(+12.3%)
$7.60 M(-0.2%)
Jun 2010
-
$1.26 M(-21.9%)
$7.62 M(+1.2%)
Mar 2010
-
$1.62 M(-50.9%)
$7.52 M(+5.3%)
Dec 2009
$7.14 M(+5.5%)
$3.30 M(+129.8%)
$7.14 M(+34.5%)
Sep 2009
-
$1.44 M(+22.5%)
$5.31 M(+2.3%)
Jun 2009
-
$1.17 M(-5.6%)
$5.19 M(-14.0%)
Mar 2009
-
$1.24 M(-15.2%)
$6.04 M(-10.9%)
Dec 2008
$6.77 M(-67.1%)
$1.46 M(+11.4%)
$6.77 M(-56.1%)
Sep 2008
-
$1.31 M(-34.8%)
$15.42 M(-4.2%)
Jun 2008
-
$2.02 M(+2.0%)
$16.10 M(-21.8%)
Mar 2008
-
$1.98 M(-80.5%)
$20.58 M(-0.1%)
Dec 2007
$20.59 M(+355.1%)
$10.12 M(+409.5%)
$20.59 M(+68.6%)
Sep 2007
-
$1.99 M(-69.5%)
$12.21 M(+8.0%)
Jun 2007
-
$6.50 M(+227.3%)
$11.30 M(+73.6%)
Mar 2007
-
$1.99 M(+14.3%)
$6.51 M(+22.9%)
Dec 2006
$4.53 M(+112.3%)
$1.74 M(+61.4%)
$5.30 M(-5.8%)
Sep 2006
-
$1.08 M(-37.0%)
$5.62 M(+22.7%)
Jun 2006
-
$1.71 M(+120.9%)
$4.58 M(+58.4%)
Mar 2006
-
$774.00 K(-62.5%)
$2.89 M(+35.8%)
Dec 2005
$2.13 M(+164.1%)
$2.06 M(+5648.7%)
$2.13 M(+187.7%)
Sep 2005
-
$35.90 K(+76.0%)
$740.70 K(-1.1%)
Jun 2005
-
$20.40 K(+87.2%)
$748.70 K(-5.0%)
Mar 2005
-
$10.90 K(-98.4%)
$788.20 K(-2.3%)
Dec 2004
$807.00 K(+447.5%)
$673.50 K(+1434.2%)
$807.00 K(+332.5%)
Sep 2004
-
$43.90 K(-26.7%)
$186.60 K(+6.2%)
Jun 2004
-
$59.90 K(+101.7%)
$175.70 K(+19.7%)
Mar 2004
-
$29.70 K(-44.1%)
$146.80 K(-3.2%)
Dec 2003
$147.40 K(-11.1%)
$53.10 K(+60.9%)
$151.70 K(+0.4%)
Sep 2003
-
$33.00 K(+6.5%)
$151.10 K(-1.8%)
Jun 2003
-
$31.00 K(-10.4%)
$153.90 K(-3.7%)
Mar 2003
-
$34.60 K(-34.1%)
$159.80 K(-3.6%)
Dec 2002
$165.80 K(-43.2%)
$52.50 K(+46.6%)
$165.80 K(-5.5%)
Sep 2002
-
$35.80 K(-3.0%)
$175.50 K(-11.5%)
Jun 2002
-
$36.90 K(-9.1%)
$198.40 K(-12.4%)
Mar 2002
-
$40.60 K(-34.7%)
$226.50 K(-22.4%)
Dec 2001
$291.80 K(-23.6%)
$62.20 K(+6.0%)
$291.70 K(-35.1%)
Sep 2001
-
$58.70 K(-9.7%)
$449.80 K(+10.6%)
Jun 2001
-
$65.00 K(-38.6%)
$406.70 K(-3.1%)
Mar 2001
-
$105.80 K(-52.0%)
$419.50 K(+9.8%)
Dec 2000
$381.90 K(-74.9%)
$220.30 K(+1312.2%)
$381.90 K(+47.2%)
Sep 2000
-
$15.60 K(-79.9%)
$259.40 K(-61.2%)
Jun 2000
-
$77.80 K(+14.1%)
$669.20 K(-34.9%)
Mar 2000
-
$68.20 K(-30.3%)
$1.03 M(-32.5%)
Dec 1999
$1.52 M(-26.9%)
$97.80 K(-77.0%)
$1.52 M(+6.9%)
Sep 1999
-
$425.40 K(-2.6%)
$1.43 M(+42.5%)
Jun 1999
-
$436.80 K(-22.6%)
$1.00 M(+77.4%)
Mar 1999
-
$564.20 K
$564.20 K
Dec 1998
$2.09 M(+1169.0%)
-
-
Dec 1997
$164.40 K(+272.8%)
-
-
Dec 1996
$44.10 K
-
-

FAQ

  • What is Protalix BioTherapeutics annual SGA?
  • What is the all time high annual SGA for Protalix BioTherapeutics?
  • What is Protalix BioTherapeutics annual SGA year-on-year change?
  • What is Protalix BioTherapeutics quarterly SGA?
  • What is the all time high quarterly SGA for Protalix BioTherapeutics?
  • What is Protalix BioTherapeutics quarterly SGA year-on-year change?
  • What is Protalix BioTherapeutics TTM SGA?
  • What is the all time high TTM SGA for Protalix BioTherapeutics?
  • What is Protalix BioTherapeutics TTM SGA year-on-year change?

What is Protalix BioTherapeutics annual SGA?

The current annual SGA of PLX is $14.96 M

What is the all time high annual SGA for Protalix BioTherapeutics?

Protalix BioTherapeutics all-time high annual SGA is $20.59 M

What is Protalix BioTherapeutics annual SGA year-on-year change?

Over the past year, PLX annual SGA has changed by +$3.25 M (+27.73%)

What is Protalix BioTherapeutics quarterly SGA?

The current quarterly SGA of PLX is $2.60 M

What is the all time high quarterly SGA for Protalix BioTherapeutics?

Protalix BioTherapeutics all-time high quarterly SGA is $10.12 M

What is Protalix BioTherapeutics quarterly SGA year-on-year change?

Over the past year, PLX quarterly SGA has changed by -$1.07 M (-29.29%)

What is Protalix BioTherapeutics TTM SGA?

The current TTM SGA of PLX is -$1.54 B

What is the all time high TTM SGA for Protalix BioTherapeutics?

Protalix BioTherapeutics all-time high TTM SGA is -$2.23 M

What is Protalix BioTherapeutics TTM SGA year-on-year change?

Over the past year, PLX TTM SGA has changed by -$1.55 B (-11171.43%)